Fosquidone is a water soluble analogue of the drug mitoquidone, which was the first of a series of pentacyclic pyrroloquinones developed as anti-tumour agents. Mitoquidone was of particular interest because of its broad spectrum of activity in rodent solid tumours and xenografts with no demonstrable activity in P388 or L1210 leukaemia (Fenton et al., 1989) . The basis of its antitumour efficacy was unknown but these characteristics suggested a different mechanism of action from that of conventional cytotoxic agents. Phase I trials with Mitoquidone were closed prematurely because of solubility problems, and the possible occurrence of intravascular drug precipitation (Speth et al., 1988) . However antitumour efficacy had been recorded in one patient before the study closed.
Fosquidone has similar biological characteristics to the parent compound, and is much more soluble by virtue of its phosphate side chain. A particular feature of preclinical studies was its schedule-dependency in solid tumours; daily repeated i.v. administration was more effective than high dose intermittent administration. Antitumour activity in human tumour xenografts was seen in breast, ovary, colon and head and neck tumours (Fenton et al., 1989) .
Phase I trials with Fosquidone were conducted with three schedules; single dose weekly, daily for 5 days every 3 weeks, and three times per week for 3 consecutive weeks (Cassidy et al., 1989; Smyth et al., 1990; Planting et al., 1990 (Smyth et al., 1990 Responses assessed after two courses are given in Analysis of these Phase II studies has revealed no significant activity for Fosquidone, when using a 5 daily schedule every 3 weeks, despite the fact that none of the patients treated had received prior chemotherapy.
The experimental antitumour efficacy of Fosquidone remains unexplained. The drug was inactive when tested in vitro in a number of cell lines, while clearly effective in vivo in several tumour models (Fenton et al., 1989) . Possible explanations could include metabolic conversion to an active species, or else the involvement of immunomodulatory or vascular mechanisms, but experimental data in support of any of these hypotheses are not yet available. Another striking feature of the drug's experimental activity is its clear schedule dependency, with long term exposure being the most effective in murine tumour models. For this reason additional Phase I trials have been initiated in an attempt to simulate the experimentally active schedules, using long term infusions and also orally formulated Fosquidone. However, further development of antitumour agents based on the pentacyclic pyrroloquinone structure may depend on a clearer understanding of the basis for its activity.
